MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, CLDX has $511,254K in assets. $55,028K in debts. $35,729K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
892.18%
Quick Ratio
892.18%
Cash Ratio
69.41%
Debt to Asset Ratio
10.76%
Unit: Thousand (K) dollars
Assets Breakdown
    • Maturing in one year or less-Cor...
    • Maturing in one year or less-UST...
    • Maturing after one year through ...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued expenses
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
35,729 28,871 36,037 23,044
Maturing in one year or less-USTreasury And Government
130,939 151,749 154,098 -
Maturing after one year through three years-USTreasury And Government
37,550 42,485 54,939 -
Maturing in one year or less-Corporate Debt Securities
205,519 257,437 305,897 -
Maturing after one year through three years-Corporate Debt Securities
41,721 38,031 32,252 -
Marketable securities
415,729 489,702 547,186 607,293
Accounts and other receivables
230 2,015 90 90
Prepaid and other current assets
7,534 14,076 21,026 17,977
Total current assets
459,222 534,664 604,339 648,404
Property and equipment, net
7,396 5,334 4,829 4,392
Operating lease right-of-use assets, net
2,012 2,437 2,717 3,121
Intangible assets
27,190 27,190 27,190 27,190
Other assets
15,434 13,358 9,364 9,300
Total assets
511,254 582,983 648,439 692,407
Accounts payable
10,359 1,180 4,267 2,073
Accrued expenses
38,418 47,029 39,715 28,424
Current portion of operating lease liabilities
1,465 1,552 1,553 1,536
Current portion of other long-term liabilities
1,230 1,230 930 930
Total current liabilities
51,472 50,991 46,465 32,963
Long-term portion of operating lease liabilities
443 784 1,068 1,495
Other long-term liabilities
3,113 4,043 2,543 2,543
Convertible preferred stock, .01 par value 3,000,000 shares authorized no shares issued and outstanding at june 30, 2025 and december 31, 2024
---0
Total liabilities
55,028 55,818 50,076 37,001
Common stock, .001 par value 297,000,000 shares authorized 66,568,971 and 66,549,442 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively
67 67 66 66
Additional paid-in capital
2,346,303 2,337,453 2,327,196 2,317,621
Accumulated other comprehensive income
2,522 3,626 3,765 3,339
Accumulated deficit
-1,892,666 -1,813,981 -1,732,664 -1,665,620
Total stockholders' equity
456,226 527,165 598,363 655,406
Total liabilities and stockholders' equity
511,254 582,983 648,439 692,407
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Maturing in one year orless-Corporate Debt Securities$205,519K Maturing in one year orless-USTreasury And Government$130,939K Maturing after one yearthrough three...$41,721K Maturing after one yearthrough three...$37,550K Marketable securities$415,729K Cash and cashequivalents$35,729K Prepaid and othercurrent assets$7,534K Accounts and otherreceivables$230K Total current assets$459,222K Intangible assets$27,190K Other assets$15,434K Property and equipment,net$7,396K Operating leaseright-of-use assets, net$2,012K Total assets$511,254K Total liabilities andstockholders' equity$511,254K Total stockholders'equity$456,226K Total liabilities$55,028K Accumulated deficit-$1,892,666K Additional paid-in capital$2,346,303K Total currentliabilities$51,472K Other long-termliabilities$3,113K Long-term portion ofoperating lease...$443K Accumulated othercomprehensive income$2,522K Common stock, .001 parvalue 297,000,000...$67K Accrued expenses$38,418K Accounts payable$10,359K Current portion ofoperating lease...$1,465K Current portion of otherlong-term liabilities$1,230K

Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. (CLDX)